Finance

Lists
Why is INBX up २.४३%?
Dive Deeper
INBX:NASDAQ
Inhibrx Biosciences Inc
US$ ९५.०१
+२.४३%
(+२.२५) 1D
अक्टोबर ९, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INBX...
Open
US$ ९२.७०
High
US$ ९५.८१
Low
US$ ९२.७०
Mkt. cap
१.४० अरब
Avg. vol.
३.२० लाख
Volume
८६.८२ हजार
52-wk high
US$ १५५.२९
52-wk low
US$ २८.१६
EPS
-US$ ८.८८
Shares outstanding
१.४७ करोड
No. of employees
११०
Open
US$ ९२.७०
High
US$ ९५.८१
Low
US$ ९२.७०
Mkt. cap
१.४० अरब
Avg. vol.
३.२० लाख
Volume
८६.८२ हजार
52-wk high
US$ १५५.२९
52-wk low
US$ २८.१६
EPS
-US$ ८.८८
Shares outstanding
१.४७ करोड
No. of employees
११०
News stories
From web sources and news partners
About Inhibrx Biosciences Inc
CEO-
Employees११०
Founded२०२४
HeadquartersLa Jolla, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Websiteinhibrx.com
Analyst ratings
Based on 3 analysts giving stock ratings to INBX in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for INBX in the last 3 months.
Highest
Current US$ ९५.०१
US$ ३२५.०० (+२४२.०७%)
Average
US$ २६६.६७ (+१८०.६८%)
Lowest
US$ २३०.०० (+१४२.०८%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Buy
Reiterated
US$ २४५.००
+१५७.९%
09/09/2026
Oliver McCammon
LifeSci Capital
Buy
Maintained
US$ २३०.००
+१४२.१%
09/08/2026
Dara Azar
Stifel Nicolaus
Buy
Maintained
US$ ३२५.००
+२४२.१%
08/21/2026
Unknown Analyst
Stifel Nicolaus
Buy
Initiated
US$ १५०.००
+५७.९%
04/08/2026
Last report
२०२६ अगस्ट १३
Fiscal period
Q2 2026
-US$ २.३४ / -US$ २.२८
-२.६३%miss
Revenue / Est. (USD)
- / ०.००
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
२.८५ करोड
२.५३ करोड
२.५२ करोड
२.३९ करोड
Cost of revenue
२.८५ करोड
२.५३ करोड
२.५२ करोड
२.३९ करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
५२.७७ लाख
५५.७४ लाख
५७.१० लाख
८२.५० लाख
Operating expense
५२.७७ लाख
५५.७४ लाख
५७.१० लाख
८२.५० लाख
Total operating expenses
३.३८ करोड
३.०९ करोड
३.०९ करोड
३.२१ करोड
Operating income
-३.३८ करोड
-३.०९ करोड
-३.०९ करोड
-३.२१ करोड
Other non operating income
-४६.०० हजार
-३९.०० हजार
-१२.०० हजार
-६८.०० हजार
EBT including unusual items
-३.५३ करोड
-३.२८ करोड
-३.३४ करोड
-३.६६ करोड
EBT excluding unusual items
-३.५३ करोड
-३.२८ करोड
-३.३४ करोड
-३.६६ करोड
Income tax expense
-
-
-
३.०० हजार
Effective tax rate
-
-
-
-०.०१%
Other operating expenses
-
-
-
-
Net income
-३.५३ करोड
-३.२८ करोड
-३.३४ करोड
-३.६६ करोड
Net profit margin
-
-
-
-
Earnings per share
-२.२८
-२.११
-२.१५
-२.३४
Interest and investment income
१७.८३ लाख
१३.१३ लाख
१०.०७ लाख
१२.६३ लाख
Interest expense
-३१.८१ लाख
-३१.८५ लाख
-३५.०९ लाख
-५६.९३ लाख
Net interest expenses
-१३.९८ लाख
-१८.७२ लाख
-२५.०२ लाख
-४४.३० लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-३.३२ करोड
-३.०४ करोड
-३.०४ करोड
-३.१६ करोड
Gain or loss from assets sale
३.०० हजार
९.०० हजार
-
१४.०० हजार
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू